NO970783L - Fremgangsmåte for å hindre endometrialkreft - Google Patents

Fremgangsmåte for å hindre endometrialkreft

Info

Publication number
NO970783L
NO970783L NO970783A NO970783A NO970783L NO 970783 L NO970783 L NO 970783L NO 970783 A NO970783 A NO 970783A NO 970783 A NO970783 A NO 970783A NO 970783 L NO970783 L NO 970783L
Authority
NO
Norway
Prior art keywords
endometrial cancer
procedure
preventing
preventing endometrial
hexamethylenimino
Prior art date
Application number
NO970783A
Other languages
English (en)
Norwegian (no)
Other versions
NO970783D0 (no
Inventor
Susan Margaret Boss
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO970783D0 publication Critical patent/NO970783D0/no
Publication of NO970783L publication Critical patent/NO970783L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO970783A 1994-08-22 1997-02-20 Fremgangsmåte for å hindre endometrialkreft NO970783L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29385394A 1994-08-22 1994-08-22
PCT/US1995/010651 WO1996005833A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting endometrial cancer

Publications (2)

Publication Number Publication Date
NO970783D0 NO970783D0 (no) 1997-02-20
NO970783L true NO970783L (no) 1997-02-20

Family

ID=23130867

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970783A NO970783L (no) 1994-08-22 1997-02-20 Fremgangsmåte for å hindre endometrialkreft

Country Status (17)

Country Link
EP (1) EP0777476A4 (ru)
JP (1) JPH10504824A (ru)
KR (1) KR970705387A (ru)
AU (1) AU688112B2 (ru)
CA (1) CA2198119A1 (ru)
CZ (1) CZ51897A3 (ru)
FI (1) FI970717A0 (ru)
HU (1) HUT76890A (ru)
IL (1) IL115022A (ru)
MX (1) MX9701327A (ru)
MY (1) MY113757A (ru)
NO (1) NO970783L (ru)
NZ (1) NZ292017A (ru)
RU (1) RU2161964C2 (ru)
TW (1) TW404834B (ru)
WO (1) WO1996005833A1 (ru)
ZA (1) ZA956994B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN115825414B (zh) * 2023-01-09 2023-04-25 中国医学科学院北京协和医院 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
BR9406616A (pt) * 1993-04-07 1996-02-06 Ligand Pharm Inc Método para triagem de agonistas receptores
JPH07149638A (ja) * 1993-10-15 1995-06-13 Eli Lilly & Co 耐性新生物の治療法
ZA956988B (en) * 1994-08-22 1997-02-21 Lilly Co Eli Methods of inhibiting primary endometrial hyperplasia.
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Also Published As

Publication number Publication date
MX9701327A (es) 1997-05-31
AU3370095A (en) 1996-03-14
CZ51897A3 (en) 1997-06-11
MY113757A (en) 2002-05-31
WO1996005833A1 (en) 1996-02-29
NZ292017A (en) 2000-07-28
FI970717A (fi) 1997-02-20
JPH10504824A (ja) 1998-05-12
CA2198119A1 (en) 1996-02-29
KR970705387A (ko) 1997-10-09
NO970783D0 (no) 1997-02-20
EP0777476A4 (en) 1999-06-23
RU2161964C2 (ru) 2001-01-20
AU688112B2 (en) 1998-03-05
IL115022A (en) 2000-07-31
IL115022A0 (en) 1998-06-15
FI970717A0 (fi) 1997-02-20
ZA956994B (en) 1997-02-21
EP0777476A1 (en) 1997-06-11
HUT76890A (en) 1997-12-29
TW404834B (en) 2000-09-11

Similar Documents

Publication Publication Date Title
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
DK0659417T3 (da) Fremgangsmåder til inhibering af dysfunktionel blødning fra livmoderen
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944925D0 (no) Fremgangsmåte for å öke libido i post-menopausale kvinner
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
NO971029L (no) Fremgangsmåter for hemming av endometriale metoser
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
NO970787L (no) Fremgangsmåte for hemming av primær endometrial hyperplasi
NO983452L (no) FremgangsmÕter for Õ hemme muskuloaponeurotisk fibromatose (desmoide tumorer)
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO983451L (no) FremgangsmÕte for hemming av colontumorer
NO973470L (no) Fremgangsmåte for minsking av serumkalsiumnivåer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application